TY - JOUR T1 - SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T-cell receptors JF - medRxiv DO - 10.1101/2020.05.20.20107813 SP - 2020.05.20.20107813 AU - Alina S. Shomuradova AU - Murad S. Vagida AU - Savely A. Sheetikov AU - Ksenia V. Zornikova AU - Dmitriy Kiryukhin AU - Aleksei Titov AU - Iuliia O. Peshkova AU - Alexandra Khmelevskaya AU - Dmitry V. Dianov AU - Maria Malasheva AU - Anton Shmelev AU - Yana Serdyuk AU - Dmitry V. Bagaev AU - Anastasia Pivnyuk AU - Dmitrii S. Shcherbinin AU - Alexandra V. Maleeva AU - Naina T. Shakirova AU - Artem Pilunov AU - Dmitry B. Malko AU - Ekaterina G. Khamaganova AU - Bella Biderman AU - Alexander Ivanov AU - Mikhail Shugay AU - Grigory A. Efimov Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/25/2020.05.20.20107813.abstract N2 - Understanding the determinants of adaptive immune response to SARS-CoV-2 is critical for fighting the ongoing COVID-19 pandemic. Here we assayed both antibody and T-cell reactivity to SARS-CoV-2 antigens in COVID-19 convalescent patients and healthy donors sampled before and during the pandemic. Our results show that while anti-SARS-CoV-2 antibodies can distinguish convalescent patients from healthy donors, the magnitude of T-cell response was more pronounced in healthy donors sampled during COVID-19 pandemic than in donors sampled before the outbreak. This hints at the possibility that some individuals have encountered the virus but were protected by T-cell cross-reactivity observed. A public and diverse T-cell response was observed for two A*02-restricted SARS-CoV-2 epitopes, revealing a set of T-cell receptor motifs displaying germline-encoded features. Bulk CD4+ and CD8+ T-cell response to SARS-CoV-2 glycoprotein S is characterized by multiple groups of homologous T-cell receptor sequences some of which are shared across multiple donors, indicating the existence of immunodominant epitopes. Overall, our findings indicate that T cells form an efficient response to SARS-CoV-2 and alongside the antibodies can serve as a useful biomarker for surveying SARS-CoV-2 exposure and immunity. We hope that data, including the set of specific T-cell receptors identified in this study can serve as a basis for future developments of SARS-CoV-2 vaccinations and monitoring.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialthe study did not involve a clinical trialFunding StatementMikhail Shugay was supported by RFBR grant No 19-34-70011. Alexander Ivanov was supported by the Ministry of Science and Higher Education of the Russian Federation [Agreement No. 075-15-2019-1660].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTCR sequencing data was deposited to the VDJdb database (vdjdb.cdr3.net) and attached to this article as Extended data tables https://www.vdjdb.cdr3.net ER -